Davern Capital Partners, LP
NY, NY · CIK 2003147 · 13F filing filed 2026-08-13
SEC-registered investment adviser since 2025 · limited partnership
- Assets managed$715.1m
- Staff4 · 3 in investment roles
- Main clients (by assets)Sovereign wealth funds 92%, Private funds 8%
- Private funds1 (1 hedge) · $55.1m gross assets
- Main officeNew York, NY
- Websitedaverncapital.com
- Form ADV · 2026-03-27SEC adviser record
- Legal entityDAVERN CAPITAL PARTNERS, LP (US)
$586.5m
reported value
+60.9% vs Q1 2026
15positions
86.8%in top 10
3 new
10 added
2 reduced
5 sold out
vs Q1 2026
Holdings, Q2 2026
The small lines show how much was held over the last 4 quarters (adjusted for stock splits).
| Security | Value | Change |
|---|---|---|
| BIONTECH SE BNTX | $70.2m11.97% | Added +449.5k |
| ROIVANT SCIENCES LTD ROIV | $68.4m11.66% | Added +1.1m |
| ROYALTY PHARMA PLC RPRX | $64.8m11.05% | Added +635.8k |
| IONIS PHARMACEUTICALS INC IONS | $63.3m10.80% | Added +411.8k |
| INSMED INC INSM | $59.7m10.18% | Added +377.3k |
| REGENERON PHARMACEUTICALS REGN | $57.8m9.85% | Added +47.8k |
| LEGEND BIOTECH CORP LEGN | $34.4m5.87% | Reduced -123.2k |
| ALNYLAM PHARMACEUTICALS INC ALNY | $34.0m5.80% | New |
| NATERA INC NTRA | $32.3m5.51% | Reduced -25.0k |
| STRUCTURE THERAPEUTICS INC GPCR | $23.9m4.08% | Added +319.6k |
| MINERALYS THERAPEUTICS INC MLYS | $23.2m3.95% | Added +411.6k |
| VERA THERAPEUTICS INC VERA | $21.4m3.65% | New |
| GENERATE BIOMEDICINES INC GENB | $13.9m2.37% | Added +232.9k |
| PROCEPT BIOROBOTICS CORP PRCT | $10.5m1.79% | Added +203.7k |
| AVALO THERAPEUTICS INC AVTX | $8.7m1.48% | New |
Sold out since Q1 2026
| Security | Value then |
|---|---|
| PFIZER INC PFE | $44.8m1.6m shares |
| ARGENX SE ARGX | $25.6m35.0k shares |
| ELI LILLY & CO LLY | $25.1m27.3k shares |
| ABIVAX SA ABVX | $8.7m78.1k shares |
| VIRIDIAN THERAPEUTICS INC VRDN | $5.9m302.5k shares |